why choose us

300×250 Ad Slot

Research Article: Dual-Pathway Inhibition with Rivaroxaban and Low-Dose Aspirin Does Not Alter Immune Cell Responsiveness and Distribution in Patients with Coronary Artery Disease

Date Published: 2023-12-06

Abstract:
Cardiovascular diseases (CVD) are the leading cause of death globally. Inflammation is an important driver of CVD where tissue damage may lead to the formation of deadly thrombi. Therefore, antithrombotic drugs, such as platelet inhibitors, are crucial for secondary risk prevention in coronary artery disease (CAD) and peripheral artery disease (PAD). For severe forms of the disease, dual-pathway inhibition (DPI) where low-dose aspirin is combined with rivaroxaban has shown improved efficacy in reducing cardiovascular mortality.

Introduction:
The leading cause of mortality globally is cardiovascular disease (CVD) [1]. Although there are many underlying causes for CVD, coronary artery disease (CAD) and peripheral artery disease (PAD) are primarily caused by atherosclerotic plaques within arterial walls. Tissue injury associated with atherosclerosis, particularly plaque rupture, can activate platelets and proteins of the coagulation cascade, resulting in the formation of thrombi that restrict blood flow through the artery, potentially leading to ischemic…

Read more

300×250 Ad Slot